Drug Information: Ocrelizumab is a fully human anti-CD20 monoclonal antibody which in preclinical studies was more powerful than rituximab. It is taken intravenously.
Side Effects: Infusion-related reactions (74%), severe (grade 3/4) reactions (9%)
Clinical Trials: A European Phase I study reported a 38% response rate in relapsed and refractory follicular lymphoma patients. However, half progressed within less than one year following their initial response.
Published Studies
F. Morschhauser et al. "Results of a Phase I/II Study of Oreclizumab." Annals of Oncology (2010).
No comments:
Post a Comment